Analysts Are Bullish on Top Healthcare Stocks: Alnylam Pharma (ALNY), Foghorn Therapeutics (FHTX)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alnylam Pharma (ALNY – Research Report) and Foghorn Therapeutics (FHTX – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Alnylam Pharma (ALNY)
In a report released yesterday, Salveen Richter from Goldman Sachs maintained a Buy rating on Alnylam Pharma, with a price target of $580.00. The company’s shares closed last Monday at $370.91.
According to TipRanks.com, Richter is a 4-star analyst with an average return of
Alnylam Pharma has an analyst consensus of Strong Buy, with a price target consensus of $501.06, a 32.6% upside from current levels. In a report released yesterday, Needham also maintained a Buy rating on the stock with a $529.00 price target.
See the top stocks recommended by analysts >>
Foghorn Therapeutics (FHTX)
In a report released today, Jeet Mukherjee from BTIG reiterated a Buy rating on Foghorn Therapeutics, with a price target of $11.00. The company’s shares closed last Monday at $6.38.
According to TipRanks.com, Mukherjee is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Foghorn Therapeutics with a $11.38 average price target, which is a 110.0% upside from current levels. In a report released yesterday, Stifel Nicolaus also maintained a Buy rating on the stock with a $12.00 price target.
